Literature DB >> 6890407

Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis.

D L Longo, M Wesley, D Howser, S M Hubbard, T Anderson, R C Young.   

Abstract

We tested the efficacy of scopolamine delivered by transdermal patch in preventing emesis induced by cisplatin as a single agent or in combination. The administration of scopolamine by transdermal patch resulted in acceptable side effects but was ineffective in controlling cisplatin-induced emesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890407

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

Review 1.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  5-Hydroxytryptamine is emetogenic in the house musk shrew, Suncus murinus.

Authors:  Y Torii; H Saito; N Matsuki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

3.  Transdermal hyoscine induced unilateral mydriasis.

Authors:  Breffni Hannon; Valerie Jennings; Marie Twomey; Maeve O'Reilly
Journal:  BMJ Case Rep       Date:  2012-03-20

Review 4.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

Review 5.  Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

Review 6.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.